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Disease modelingMyosin-binding protein C (Mybpc3)-targeted knock-inmice (KI) recapitulate typical aspects of human hypertro-
phic cardiomyopathy. We evaluatedwhether these functional alterations can be reproduced in engineered heart
tissue (EHT) and yield novel mechanistic information on the function of cMyBP-C. EHTs were generated from
cardiac cells of neonatal KI, heterozygous (HET) or wild-type controls (WT) and developed without apparent
morphological differences. KI had 70% and HET 20% lower total cMyBP-C levels thanWT, accompanied by elevat-
ed fetal gene expression. Under standard culture conditions and spontaneous beating, KI EHTs showed more
frequent burst beating than WT and occasional tetanic contractions (14/96). Under electrical stimulation
(6 Hz, 37 °C) KI EHTs exhibited shorter contraction and relaxation times and a twofold higher sensitivity to ex-
ternal [Ca2+]. Accordingly, the sensitivity to verapamil was 4-fold lower and the response to isoprenaline or the
Ca2+ sensitizer EMD57033 2- to 4-fold smaller. The loss of EMDeffect was veriﬁed in 6-week-old KImice in vivo.
HET EHTs were apparently normal under basal conditions, but showed similarly altered contractile responses to
[Ca2+], verapamil, isoprenaline and EMD. In contrast, drug-induced changes in intracellular Ca2+ transients
(Fura-2) were essentially normal. In conclusion, the present ﬁndings in auxotonically contracting EHTs support
the idea that cMyBP-C's normal role is to suppress force generation at low intracellular Ca2+ and stabilize the
power-stroke step of the cross bridge cycle. Pharmacological testing in EHT unmasked a disease phenotype in
HET. The altered drug response may be clinically relevant.
© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.p2a2, ATPase, Ca2+ transporting,
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Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac
disease with an estimated prevalence of 1:500 [1,2]. Mutations in genes
encoding proteins of the sarcomere are themost frequent cause of HCM
with mutations in MYH7 (β-myosin heavy chain, β-MHC) andMYBPC3
(cardiac myosin-binding protein C, cMyBP-C) prevailing [3–6]. The
phenotype of HCM patients is typically heterogeneous with some pa-
tients developing dyspnea, chest pain, heart failure, arrhythmias and
sudden cardiac death, and others remaining asymptomatic until late
in life [2,7]. The overall genotype–phenotype correlation is poor [8],
suggesting that other unknown factors such as modiﬁer gene variants
[4,9,10], epigenetic mechanisms or environmental factors affect disease
expression. Risk prediction may be improved by the identiﬁcation of
early clinical signs (e.g. diastolic dysfunction [11]) or biomarkers [12].
A potential future alternative is tomodelHCM in a patient-speciﬁcman-
ner via induced pluripotent stem (iPS) cells [13]. Recent studies recapit-
ulated aspects of LQT syndromes [14,15] or cardiomyopathies [16,17] in
iPS cells, but there is a large step from an in vitro cellular phenotype tonse.
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apparent clinical phenotype develops relatively late in life. A key pre-
requisite is therefore the development of high content experimental
models that allowdeﬁning the phenotype of iPS-derived cardiomyocytes
in a standardized, robust and quantitative manner. One such model
could be an automated and miniaturized 24-well-assay based on our
engineered heart tissue (EHT) technology [18,19]. Advantages of EHTs
are their 3D structure mimicking native heart muscle and the possibility
to retrieve in depth information about contractile function.
Here we studied in mice two questions relevant to future iPS-
mediated disease modeling of cardiomyopathies: is it possible at all to
detect a speciﬁc phenotype in EHT derived from a genetically deﬁned,
characterized mouse model of HCM? Does this technology help to
better understand the disease?
We chose a well characterized mouse model of HCM which, from a
genetic point of view, mimics the human disease as close as possible,
and studied it at the homozygous and heterozygous state. Homozygous
Mybpc3-targeted knock-in (KI) mice express different splice variants of
cMyBP-C, exhibit a 90% reduction of total cMyBP-C protein levels and
develop early cardiac hypertrophy, left ventricular dilatation and re-
duced fractional shortening in young adulthood [20]. Heterozygous
mice (HET) have only a slight reduction in cMyBP-C levels [20] and,
except for diastolic dysfunction without hypertrophy, exhibit no appar-
ent cardiac phenotype until the age of 18 months [20,21]. Thus, HET
mice mimic the often mild phenotype of cMyBP-C-associated HCM.
Skinned cardiomyocytes or trabeculae from both KI and HET mice
exhibited increased Ca2+ sensitivity [21], suggesting that increased
Ca2+ sensitivity is the primary consequence of the defect in cMyBP-C
and directly responsible for diastolic dysfunction [21]. On this back-
ground we analyzed the contractile performance of wild-type (WT)
and KI/HET-derived EHTs under baseline conditions and in the presence
of drugs altering intracellular Ca2+ concentrations (extracellular Ca2+
concentrations, isoprenaline, verapamil) or the myoﬁlament response
to Ca2+ (EMD 57033) [22,23].
2. Materials and methods
See the online Supplemental ﬁle for a detailed description of
materials and methods and statistical analyses.
2.1. Animals
The investigation conforms to the guide for care anduse of laboratory
animals published by the NIH (Publication No. 85-23, revised 1985). KI
and HET mice were described previously (Supplemental Fig. 1; [20])
and maintained on a Black Swiss background, respectively. WT mice
from the Black Swiss background served as respective controls.
2.2. Generation, culture and measurements of EHT
EHTs were generated according to our 24-well-EHT silicone post
method as previously described for neonatal rat heart cells [18]. Major
differences to the methods with rats were a higher cell density and a
pulse of cytosine β-D-arabinofuranoside. In brief, freshly isolated,
unpuriﬁed heart cells from 0 to 1 day old mice were resuspended at
a ﬁnal density of 6.8 × 106 cells/ml culture medium with bovine
ﬁbrinogen (ﬁnal concentration 5 mg/ml, Sigma F4753), aprotinin
2.5 μg/ml and 10% Matrigel (BD Bioscience 356235). The reconstitution
mix (97 μl/EHT) was mixed brieﬂy with thrombin (3 μl/EHT, 100 U/ml,
Sigma T7513) and pipetted into rectangular agarose casting molds
(L × W × D 12 × 3 × 4 mm) in a 24-well-plate. Prior to this pipetting
step, silicone racks with 4 pairs of elastic silicone posts each were placed
onto the 24-well-plate (6 racks per plate) in a way that pairs of posts
reached from above into the casting molds containing the cell–
ﬁbrinogen–thrombin mix. Fibrin polymerization (37 °C, 7% CO2, 2 h)
led to a rectangular ﬁbrin–cell–gel formation around the tips of thesilicone posts. The racks were then transferred to fresh 24-well
plates containing culture medium (DMEM (Biochrom F0415), 10%
horse serum (Gibco 26050), 2% chick embryo extract, 1% Penicillin/
Streptomycin (Gibco 15140), insulin (10 μg/ml, Sigma I9278) and
aprotinin (33 μg/ml, Sigma A1153)) and kept in cell culture (21% oxy-
gen) for up to 4 weeks. On day 5 cytosine β-D-arabinofuranoside
(25 μg/ml, Sigma C1768) was added to culture medium for 48 h.
Spontaneous contractility of EHTs was recorded over time by a
video camera and automatically evaluated by a customized CTMV
software (Pforzheim, Germany) as recently published [18]. Contrac-
tility parameters analyzed were frequency, force, contraction and
relaxation times (T1, T2 determined at 10% of peak maximum,
respectively). To analyze contractility under constant beating rate
and perfusion a novel microscope-based set-up was constructed as
described in detail in the Supplemental Material. EHTs were
positioned in 24-well glass bottom plates (IWAKI 090615) in a cell-
culture-like incubation chamber, electrically paced (6 Hz; 7 V;
5 ms duration, S88X Stimulator, Grass, Astro-Med, Inc.) and continu-
ously perfused (37 °C, 95% O2, 5% CO2) with Tyrode's solution (in
mM: NaCl 120, KCl 5.4, MgCl2 1.0, CaCl2 0.2–1.8, NaH2PO4 0.4,
NaHCO3 22.6, glucose 5.0, Na2EDTA 0.05, ascorbic acid 0.3;
6 ml/min). Contractile parameters were evaluated by averaging
50–100 peaks using a customized software (CTMV).
2.3. Fura-2 AM staining of EHTs
EHTs were washed twice in Tyrode's solution (1.8 or 0.6 mM Ca2+,
respectively, 5 min) and incubated in Tyrode's solution (1.8 or 0.6 mM
Ca2+, respectively) containing 10 μM Fura-2 AM, and Cremophor EL
(0.75%; Sigma C5135) for 2 h at 37 °C [24]. Then EHTs were washed
with Tyrode's solution (1.8 mM Ca2+) for 5–10 min before recordings
of baseline.
2.4. Echocardiography
Transthoracic echocardiography was performed in anesthetized
mice (isoﬂurane 1.5–2%) using a Vevo 2100 System (VisualSonics,
Toronto, Canada) as previously described [21].
3. Results
3.1. Tissue-like structure formation and spontaneous force development in
murine EHT
EHTs from WT, HET and KI mice developed without apparent differ-
ences. Theﬁbrinmatrixwas remodeled over time,macroscopically visible
as a reduction in width and thickness compared to the rectangular cell–
ﬁbrin block directly after casting (Fig. 1A).
On day 3 of culture, cardiomyocytes started to form large
synchronously beating areas in all three groups of EHTs. Coherent
contractions with deﬂection of silicone posts were observed after
6–10 days of culture. Hematoxylin/eosin-stained parafﬁn sections
of 18-day-old EHTs showed cells evenly distributed in all EHTs and
aligned along the force lines (Figs. 1B and C). Immunoﬂuorescence
staining showed a dense network of longitudinally orientated cell
strands ofα-actinin-positive cardiomyocytes with distinct cross stri-
ation (Z-band) and characteristic A-band staining (doublets) of
cMyBP-C in WT and, at a reduced level, in HET and KI EHTs
(Figs. 1D–L). Staining of cMyBP-C was irregular and patchy in KI.
Cell size and the degree of cell–cell-contacts did not show apparent
differences between groups.
3.2. cMyBP-C and hypertrophic marker gene expression in EHT
Protein and/or transcript levels of cMyBP-C, markers of the hyper-
trophic gene program and Ca2+ handling proteins were determined
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Fig. 1.Morphological aspects of murine EHTs (day 18 of culture). A, Phase contrast image of WT EHT. B and C, Representative hematoxylin/eosin-stained parafﬁn section. D–I, Merged
immunoﬂuorescence analysis with staining for cMyBP-C (red), α-actinin (green) and nuclei with DRAQ5 (blue) in WT (D, G), HET (E, H) and KI (F, I) EHT. J–L, Immunoﬂuorescence
staining for cMyBP-C (red) of WT (J), HET (K) and KI (L) EHT.
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expected, cMyBP-C protein and Mybpc3 mRNA levels were markedly
lower in KI than in WT (~70%), but also ~20% lower in HET (Figs. 2A,
C and D). A band of unknown identity above the cMyBP-C band was
detected in 29% of WT and 75% of KI EHTs. The levels of β-myosin
heavy chain (β-MHC) protein and Myh7 mRNA were 3- to 4-fold
higher in HET and KI than in WT (Figs. 2A, E and F). Alpha-skeletal
actin protein (α-skAct) and Acta1mRNA levelswere similarly increased
(Figs. 2B, G and H). Atp2a2 (sarcoplasmic reticulum Ca2+-ATPase) and
Slc8a1 (sodium/calciumexchanger)mRNA levels did not differ between
the groups (Figs. 2I and J).
3.3. Contractile function under spontaneous beating
Spontaneous contractility of EHTs was evaluated on day 14 of culture
via video-optical recording. Contraction graphs were automatically
recorded and evaluated over a time period of 60 sec for the respective
EHT (examples shown in Fig. 3A). The two batches ofWT, studied togeth-
er with the respective KI/HET EHTs, differed in spontaneous beating rateand force (Figs. 3B and C), likely related to some subtle difference in cul-
ture conditions over time (e.g. serum batches). All murine EHT lines
exhibited spontaneous beating during the entire culture time. However,
whereas WT EHTs almost always beat regularly (62/67), KI often
(32/96, P b 0.001 vs. WT, Chi-square test) and HET sometimes beat in
bursts (14/44, P = 0.07 vs. WT; Supplemental Fig. 2B). Bursts in KI
were often followed by longer pauses, whereas HET and WT EHTs never
showed resting periods longer than ~ 3 sec. Interestingly, 15% of KI
EHTs (14/96) exhibited extreme prolongations of relaxation (“tetanic
contractions,” Fig. 3A, Supplemental Fig. 2A), which was never observed
in WT or HET.
To exclude the confounding inﬂuence of burst beating and tetanic
contractions, only regularly contracting EHTswere included in the anal-
ysis of rate and force. Beating rate was higher in HET and its respective
WT batch, but was 20% lower in KI than inWT (Fig. 3B). Force develop-
ment was 38% lower in the WT control corresponding to KI (Fig. 3C).
Differences between WT batches remain unexplained and indicate
that the analysis of frequency and rate under spontaneous beating
conditions are of limited value.
Fig. 2.Molecular analysis of WT, HET and KI EHTs on day 20 of culture. A, Representative Western blots of β-MHC and cMyBP-C, α-actinin served as loading control. B, Representative
Western blot of α-skAct, or α-actinin served as loading control. Ctrl means the muscle of an adult murine hint limb. C and D, Statistical analysis of cMyBP-C protein level (C) and
Mybpc3 mRNA (D). E and F, β-MHC protein level (E) and Myh7 mRNA (F). G and H, Statistical analysis of α-skAct protein level (F) and Acta1 mRNA (G). I–J, Atp2a2 (I) and Slc8a1 (J)
mRNA amounts. Number of EHTs is indicated in the bars. Ordinates give values expressed as a fold of the respective WT control value. mRNA values normalized to internal reference
gene Gs alpha. Data are means ± SEM. *P b 0.05, **P b 0.01 and ***P b 0.001 vs. WT (one-way ANOVA plus Dunnett post-tests).
Fig. 3. Spontaneous contractility ofmouse EHTsmeasuredwith video-optical recording. A, Representative picture of EHT as viewed by the video camera and evaluated by automated con-
tour recognition (blue squares), contraction peak with the evaluated parameters of contractile function and original recordings of spontaneous contractile activity in EHT generated from
WT, HET and KI. B, Rate of spontaneous beating and C, force of contraction, both measured at day 14 in culture medium containing 1.8 mMCa2+. Number of EHTs is indicated in the bars.
Data are means ± SEM. **P b 0.01 and ***P b 0.001 vs. corresponding WT (one-way ANOVA plus Bonferroni post-tests); ++P b 0.01 and +++P b 0.001 vs. WT (one-way ANOVA plus
Bonferroni post-tests).
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response-curves for Ca2+ and verapamil
To avoid confounding inﬂuences of rate, contractile function was
also analyzed at a deﬁned frequency (6 Hz) and under continuous per-
fusion. Contractile parameters did not differ between the two batches of
WT, which were therefore pooled. All EHTs showed increasing contrac-
tion amplitudes with rising extracellular [Ca2+] (0.2–1.8 mM; Fig. 4A).
Maximal twitch force at 1.8 mM [Ca2+] did not differ signiﬁcantly be-
tween the groups (Fig. 4B). However, normalization to maximal force
development of each individualmuscle showed an increased sensitivity
to external [Ca2+] in both KI and HET (Fig. 4C). Calculated EC50 values
were 0.66, 0.48 and 0.34 mM in WT, HET and KI, respectively
(P b 0.001, extra sum-of-squares F test).
Remarkably, KI EHTs showed signiﬁcantly accelerated contrac-
tion kinetics, especially in the early phase of contraction (Fig. 4D
and Supplemental Figs. 3D and E). HET EHTs did not show accelerat-
ed kinetics.
We hypothesized that the increased sensitivity of KI and HET to ex-
ternal [Ca2+]may conversely be accompanied by a decreased sensitivity
to interventions that lower intracellular [Ca2+]. Indeed, 4-fold and 1.7-Fig. 4. Contractile phenotype of electrically stimulatedWT, HET and KI. A, Representativemecha
Ca2+ concentrations from 0.2 to 1.8 mM. B, Peak force at different Ca2+ concentrations ofWT (
force of each EHT. D, Representative average peaks of WT, HET and KI expressed as % of maxim
force (1.8 mM external Ca2+), WT (n = 8), KI (n = 5) and HET (n = 11). Data are means
post-tests).fold higher concentrations of the Ca2+ channel blocker verapamil
were needed to decrease twitch force in KI and HET, respectively
(Fig. 4E). Calculated IC50 values amounted to 316, 761 and 1269 nM in
WT, HET andKI, respectively. Verapamil had no effect on twitch kinetics
(data not shown).
3.5. Contractile function under electrical pacing: contractile responses to
isoprenaline and EMD 57033
The above results showed important differences in contractile func-
tion between HET/KI and WT EHTs, which were compatible with
increased myoﬁlament Ca2+ sensitivity in these disease models [21].
To extend these results we assessed the effect of two pharmacological
interventions with distinct effects on excitation-contraction coupling:
Theβ-adrenergic agonist isoprenaline (ISO),which increases Ca2+ tran-
sients and desensitizes myoﬁlaments to Ca2+, and the Ca2+ sensitizer
EMD 57033, which increases force independent of increases in intracel-
lular Ca2+. Both drugs were used at maximally effective concentrations
(ISO 100 nM, EMD 57033 10 μM). Experiments were done at electrical
pacing (6 Hz) and 0.6 mM external Ca2+ (Fig. 5A, Supplemental
Fig. 3). Under these conditions, absolute forces were ~2.5-fold highernogram of KI, showing the positive inotropic effect of cumulative increases of extracellular
n = 7), HET (n = 12) and KI (n = 7). C, Same data as B, expressed as % of maximal peak
al peak force at 1.8 mM external Ca2+. EHTs were paced at 6 Hz. E, Effect of verapamil on
± SEM. *P b 0.05, **P b 0.01 and ***P b 0.001 vs. WT (two-way ANOVA plus Bonferroni
194 A. Stöhr et al. / Journal of Molecular and Cellular Cardiology 63 (2013) 189–198in HET and KI than inWT (Fig. 5B), again reﬂecting the increased sensi-
tivity to external [Ca2+]. Similar to the results at 1.8 mMCa2+ (Fig. 4D)
basal twitch kinetics were accelerated in KI but not in HET (Figs. 5C and
D). All EHTs responded to ISO, but its positive inotropic effectwas small-
er in KI (+100%) and in HET (+108%, P b 0.05) than in WT (+270%;
Fig. 5E). EMD 57033 markedly increased twitch force in WT (+380%),
but had only a minor effect in HET (+38%) and in KI (+29%; Fig. 5E).
Final forces were 54.4 μN in WT, 60.8 μN in HET and 98.4 μN in KI in
the presence of ISO. ISO induced a positive clinotropic and lusitropic ef-
fect inWT(−11 ms in TTP and−18 ms in TTR90) and inHET (−14 ms
in TTP and−12 ms in TTR90), but less in KI (+4 ms in TTP and−2 ms
in TTR90). EMD 57033 prolonged TTP and TTR90 in all groups to a
similar extent (Figs. 5F and G).3.6. Drug-induced changes in intracellular Ca2+ transients
Since HET and KI EHTs showed similar behaviours in contractile ex-
periments and HET represents the best model for the human disease,
we focussed on evaluating the different drug effects on Ca2+ transient
amplitudes in HET vs. WT. Differences in responses to extracellular
Ca2+ concentrations or to drugs are either due to changes in myoﬁla-
ment function or Ca2+ handling or both. To differentiate between
these possibilities, measurements of intracellular Ca2+ concentrations
were performed in WT and in HET by the use of Fura-2 AM (10 μM,Fig. 5. Effects of isoprenaline and EMD 57033 on force in electrically stimulatedWT, KI and HET
resentative average peaks of WT, KI and HET showing the effect of isoprenaline (ISO, 100 nM) a
(B) and contraction (C) and relaxation (D) times. E, Drug-induced changes in force, F, changes
conditions: ISO compared to Tyrode's solution and EMD (in 1:1000 DMSO) compared to DM
**P b 0.01 and ***P b 0.001 vs. WT, same condition (one-way ANOVA plus Dunnett post tests)37 °C; Fig. 6A). Ca2+ transient amplitude increased in the presence of
ISO in both WT and HET, but to a lower extent in HET (P b 0.01;
Fig. 6B; 0.6 mM external [Ca2+]). As expected, the Ca2+ sensitizer
EMD did not increase Ca2+ transients in WT or HET (Fig. 6C). Perfusion
with a high concentration of verapamil (1 μM, 1.8 mM external Ca2+)
lowered the Fura-2 ratio in WT and HET to a similar extent (−46% in
WT [n.s.],−43% in HET; Figs. 7B and C). To differentiate a true decrease
in peak Ca2+ transients from run down or leakage of Fura-2 we
performed time controls in which EHTs were just perfused with
Tyrode's solution. Under this condition, Fura-2 ﬂuorescence values at
340 and 380 nM indeed decreased by about 40% indicating leakage
(Supplemental Fig. 4), but the peak ratio as the indicator of intracellular
Ca2+ transients remained almost stable over a perfusion time of 45 min
(Fig. 7C). Taken together, the differential contractile drug responses
cannot be explained by differences in Ca2+ handling.3.7. Lack of response to EMD 57033 in KI but not in HET mice
To evaluatewhether the EMD57033 effects observed in EHTs extend
to the adultmouse, we tested the effect of EMD57033 (0.6 mg/kg by in-
traperitoneal injection) on cardiac function in anesthesized, 6-week-old
WT, HET and KI mice by high resolution echocardiography. KI mice
exhibited 2-fold higher left ventricular mass to body weight ratio
(LVM/BW, Fig. 8A), larger left ventricular end-diastolic and end-EHTs. Measurements were performed at 0.6 mM external Ca2+ and 6 Hz pacing. A, Rep-
nd EMD 57033 (EMD, 10 μM) expressed as % ofmaximal peak force. B, C and D, Basal force
in TTP [time to peak], and G, changes in TTR90 [time to 90% relaxation] in the following
SO (1:1000). Number of EHTs is indicated in the bars. Data are means ± SEM. *P b 0.05,
.
Fig. 6. Effects of isoprenaline and EMD 57033 on Ca2+ transients in electrically pacedWT and HET EHTs. Ca2+ transients were determined by the ratio of Fura-2 ﬂuorescence at 340 and
380 nm excitation (F340/F380 ratio). A, Normalized average peaks of WT (n = 4) and HET (n = 7) in the absence or presence of drugs. B and C, Drug-induced changes in peak Ca2+
transient amplitude (maximal F340/F380 ratio) for isoprenaline (B) and EMD (C). Measurements were performed at 0.6 mM Ca2+ and electrical pacing (4 Hz). Data are means ±SEM.
**P b 0.01 vs. basal, same genotype (paired Student's t-test) and ##P b 0.01 vs. WT, same condition (unpaired Student's t-test).
195A. Stöhr et al. / Journal of Molecular and Cellular Cardiology 63 (2013) 189–198systolic dimensions (LVIDd and LVIDs, Figs. 8B and C) and 46% lower
fractional area shortening (FAS) than WT (Fig. 8D), compatible with
the cardiomyopathy phenotype observed in KI earlier [20]. HET miceFig. 7. Effects of verapamil on Ca2+ transients in electrically pacedWTandHET EHTs. A, Normali
in the absence or presence of verapamil (1 μM). B, Drug-induced changes in peak Ca2+ transien
Ca2+ transient amplitude in the presence or absence of verapamil (time control; TC).Measurem
*P b 0.05 and **P b 0.01 vs. basal, same genotype (paired Student's t-test or two-way ANOVAdid not differ fromWT. Injection of EMD 57033 increased FAS by ~30%
and by ~25% in WT and HET, respectively, but had no effect in KI
(Fig. 8D).zed average Ca2+ transient (Fura-2 F340/F380 ratio) ofWT (n = 3) andHET EHTs (n = 6)
t amplitude after 45 min of perfusion with verapamil. C, Time-dependent changes in peak
entswere performed at 1.8 mMCa2+ and electrical pacing (2 Hz). Data aremeans ± SEM.
plus Bonferroni post tests).
Fig. 8. Effect of EMD 57033 (EMD) in 6-week-oldWT, HET and KImice asmeasured by echocardiography. A, Left ventricularmass/bodyweight ratio [LVM/BW], B, diastolic left ventricular
internal diameter [LVIDd], C, systolic left ventricular internal diameter [LVIDs] and D, fractional area shortening [FAS] were measured inWT, HET and KI before and 10 min after i.p. injec-
tion of vehicle or EMD (0.6 mg/kg in DMSO). Number of mice is indicated in bars. Data are means ± SEM. *P b 0.05 and **P b 0.01 vs. basal (paired Student's t-test); ##P b 0.01 and
###P b 0.001 vs. WT (unpaired Student's t-test).
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The present study evaluatedwhether the phenotype of homozygous
and heterozygousMybpc3-targeted KI mice can be modeled in EHT and
whether this approach provides new insights into the role of cMyBP-C.
It yielded the following main results. (1) The 24-well-ﬁbrin-EHTmeth-
od, developed for rat and human heart cells, can be utilized with some
modiﬁcations to generate engineered heart muscle from neonatal
mice. (2) KI EHTs showed spontaneous abnormalities in contraction
pattern (bursts and tetanic contraction) and, under electrical stimula-
tion at near-physiological conditions, abbreviated contractions and in-
creased sensitivity to external Ca2+. The relative contractile responses
to isoprenaline, EMD 57033 and verapamil were markedly smaller
than in WT, likely reﬂecting the higher sensitivity to external Ca2+.
(3) The lack of a positive inotropic effect of EMD 57033was reproduced
in KI mice in vivo. (4) HET EHTs were apparently normal under sponta-
neous conditions, but showed increased sensitivity to external Ca2+ and
abnormal inotropic responses similar to KI. The latter went along with
normal effects on intracellular Ca2+ transients, substantiating the hy-
pothesis that the reduced inotropic responses were mainly attributed
to the cMyBP-C mutation altering myoﬁlament function. These results
recapitulate and signiﬁcantly extend ﬁndings obtained in isolated
myocytes [21,25], engineered cardiac tissue [26] and intact heart
preparation [25] from the same or similar mouse models previously,
indicating that EHTs are useful to model a Mybpc3-related HCM-
phenotype in vitro. The increased sensitivity to external Ca2+ and, con-
versely, the decreased sensitivity to verapamil, isoprenaline and EMD
57033 of otherwise normal HET EHTs will be useful in future experi-
ments to unmask a phenotype in hiPSC-derived EHTs and may have
clinical implications.
The study is the ﬁrst to generate mouse EHTs according to our 24-
well-silicone post method [18]. Most steps of the original method
could be used without modiﬁcations, but three factors turned out to
be essential. (1) The age of mouse pups needed to be below 2 days.
Older pups gave markedly lower EHT generation efﬁciency. (2) The op-
timal initial cell density was 70% higher in mouse than in rat EHTs (0.68
vs. 0.4 Mio/100 μl). (3) In contrast to rat and human EHTs, a 48-h
pulse of 5-cytosine β-D-arabinofuranoside was necessary to preventovergrowth by ﬁbroblasts. Longer periods resulted in damage, shorter
periods in stiffened EHTs. Recently, de Lange et al. constructed
collagen I-based engineered cardiac tissue (ECT) from Mybpc3-
targeted knock-out mice and reported accelerated contraction kinetics
[26,27]. Whereas our EHTs approach supports the central ﬁnding of de
Lange et al., it goes beyond it and has some advantages. (1) ECTs have
to be manually excised from the culturing device and transferred into
organ baths for the analysis of contractile function, limiting the analysis
to a few samples. Our method, in contrast, allows parallel and automat-
ed analysis of relatively large numbers of EHTs and several experimental
groups withoutmanual handling, an advantage particularly relevant for
future experiments with hiPSC-derived EHTs. (2) In contrast to a single
end-point measurement, we repeatedly analyzed the function of EHTs
over a period of 2–3 weeks, which increased the likelihood to detect
phenotypic differences. (3) We analyzed function not only under basal
conditions, but in the presence of different concentrations of Ca2+,
isoprenaline, verapamil and EMD 57033. Important differences were
only seen under these conditions. (4) EHTs grow under “auxotonic
stretch,” i.e. they perform contractile work against the elastic posts
which they rhythmically deﬂect. This comes closest to physiological con-
ditions. In contrast, the ECT technology cultures the constructs on rigid
posts, i.e. under static/isometric conditions. The change from auxotonic
to isometric conditions induces a pathological form of hypertrophy in
rat EHTs [28], and this effect could obscure disease-speciﬁc differences
in ECTs. Indeed, markers of the fetal gene program were found at the
same concentration in ECTs from WT and KO [26], whereas they were
lower in our WT EHTs (=relatively increased in our HET and KI).
We choseMybpc3-targeted KI and HETmice because, from a genetic
point of view, theymimic the situations in patientswithHCMas close as
possible. In the KI mouse model, a common MYBPC3 mutation (13% of
all sarcomere-related mutations in an Italian cohort [29]) associated
with a severe phenotype has been introduced into the mouse genome.
The mutation located in the consensus splice donor sequence leads to
at least three different mutant mRNAs and an overall reduction of
mRNA and protein levels by 80% and 90%, respectively [20]. This
was, in isolated adult cardiomyocytes and skinned muscle ﬁbers,
accompanied by reduced, BDM-sensitive diastolic sarcomere length,
increasedmyoﬁlament Ca2+ sensitivity and severe systolic and diastolic
197A. Stöhr et al. / Journal of Molecular and Cellular Cardiology 63 (2013) 189–198dysfunction [21]. HET mice, the clinically more relevant model, exhibit
similar but milder abnormalities. KI mice do not exhibit signiﬁcantly in-
creasedmortality until late adult life [20] and HETmice, similar tomany
patients with HCM [3–6,9,30], develop only a mild disease phenotype
with diastolic dysfunction [21], but no left ventricular hypertrophy or
systolic dysfunction [20,21]. Thus, it was uncertain if EHTs, generated
from newborn mice, would exhibit a “disease phenotype” at all. The
fact that even HET showed deﬁnite functional abnormalities suggests
that the EHT format unmasks subtle abnormalities, likely because
compensatory mechanisms operating in intact animals are lacking.
The main phenotype both in KI and HET EHTs was the higher sensi-
tivity to external Ca2+ and smaller inotropic responses to all three test-
ed drugs. These abnormalities are very likely related. At 0.6 mM Ca2+
force almost reached a maximum in KI and HET, but only ~50% of max-
imum inWT(Fig. 4B). Thus,myoﬁlaments inHET andKI operate already
close to the maximum of the force-Ca2+ curve under these conditions.
Further increases in [Ca2+]i by ISO or in Ca2+-responsiveness by EMD
57033 cannot increase force to the same extent as they do in WT. The
same reason likely explains why higher concentrations of verapamil
(at 1.8 mMCa2+) were necessary before force declined. Measurements
of intracellular Ca2+ concentrations by Fura-2 principally supported the
hypothesis of the cMyBP-C mutation altering myoﬁlament function:
(1) WT and HET showed similar basal intracellular Ca2+ at 0.6 mM ex-
ternal Ca2+. (2) WT and HET showed similar intracellular Ca2+ in the
presence of EMD 57033, which, as expected, did not affect the Ca2+
transient. (3) WT and HET exhibited similar decreases in intracellular
Ca2+ under verapamil perfusion (Figs. 6 and 7). Unexpectedly, the
ISO-induced increase in peak Ca2+ was signiﬁcantly smaller in HET.
The reason remains unknown at present, but the effect could theoreti-
cally participate in the reduced contractile response to ISO. In any
case, the results advocate testing of responses to these drugs and to
different Ca2+ concentrations as the preferred intervention in future ex-
periments on HCM-derived hiPSC-EHTs. Moreover, given that verapa-
mil is a commonly prescribed drug for the treatment of HCM, the data
may have some direct clinical relevance.
HCM is a leading cause of sudden cardiac death in young people.
Thus, the abnormalities in beating rhythm and tetanic contractions in
KI are interesting and could be a surrogate of arrhythmias. They were
only seen in video-optical recordings of spontaneous beating activity,
indicating a strength of this analysis. The underlying mechanisms re-
main unknown at present, butmay be related to the presence ofmutant
cMyBP-C acting as ‘poison peptides’. An argument for this idea is the fact
that tetanic contractionswere never observed in KO EHTs, which exhib-
it increased Ca2+ sensitivity of themyoﬁlaments similar to KI (data not
shown).
Howdoes the increased sensitivity to external Ca2+ ﬁt to abbreviated
contraction in KI EHTs? And how does it ﬁt to decreased fractional area
shortening (FAS) in whole mice [20,31,32] or to the HCM phenotype in
humans? An increase in Ca2+ sensitivity normally leads to increased
force/FAS and prolonged relaxation (see EMD 57033 effect in WT,
Fig. 5, Supplemental Fig. 3). This and former studies clearly show that ab-
lation of cMyBP-C does not have the same consequences. Studies in pap-
illary muscles from cMyBP-C KO mice have shown that the lack of
cMyBP-C favors weak binding of the myosin cross bridges to actin [33],
possibly by causing a lower degree of spatial organization with some
myosin heads sticking out of the thick ﬁlaments and reaching actin.
This could be sufﬁcient to cause some of the abnormalities observed in
cMyBP-C KO andKI preparations: short diastolic sarcomere length of iso-
tonically contracting cardiomyocytes [21,25], increased sensitivity to ex-
ternal Ca2+ in isolated right atria [25] and auxotonically contracting EHT
(this study), decreased sensitivity to verapamil and EMD 57033 (this
study), and diastolic dysfunction in vivo [21]. On the other hand, ablation
of cMyBP-C strongly reduced maximal isometric force development in
isolated papillary muscles, indicating that cMyBP-C affects cross-bridge
cycle rate by supporting the power-stroke step of the cross bridge cycle
[33]. Moreover, ablation of cMyBP-C reduced time to peak shorteningand time of systolic force development in papillary muscles [33] and
whole hearts in situ [34], respectively. This is well compatible with the
abbreviated contraction time of KI seen in the present study and could
lead to reduced ejection fraction by compromising the ability of the
heart to expel blood. The fact that force in EHTs was measured under
auxotonic conditions and relatively low afterload likely explains why
maximal forces did not differ between KI andWT. HET EHTs, in contrast,
showed normal contraction kinetics and this may reﬂect the normal
systolic function in HET mice and in (heterozygous) human (MYBPC3-
related) HCM. This reasoning predicts that KI mice/EHTs are particularly
sensitive to increased afterload and may explain why KI neonates are
born with apparently normal contractile function and cardiac dimen-
sions, but develop LV dysfunction in the ﬁrst 24 h after birth [35]. The
EHT model allows to study this hypothesis directly [28].
Taken together, the present study in mice indicates that the EHT
model is suitable to detect an “in vitro disease phenotype” even in HET.
Marked differences in the sensitivity to external Ca2+ concentrations
and the contractile response to a catecholamine, a Ca2+ sensitizer and
a Ca2+ channel blocker turned out to be of particular value to unmask
a disease phenotype. The lower sensitivity to verapamil may have prac-
tical relevance for the management of patients with HCM. The results in
mouse EHTs could pave theway for future studies on iPSC-EHTmediated
disease modeling of human HCM.
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